Chronic Lymphocytic Leukemia research hub

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

This study looks at new treatments, zilovertamab vedotin alone or with nemtabrutinib, for certain B-cell lymphomas like Mantle Cell Lymphoma, Follicular Lymphoma, and Chronic Lymphocytic Leukemia. It checks how safe and effective these treatments are for people whose cancer has returned or didn’t respond to previous therapies.